

This listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims:

Claims 1-43 (Cancelled)

Claim 44 (Currently Amended) A method for treating an allergic condition in a subject, comprising administering a pharmaceutically effective amount of a therapeutic agent to the subject, said therapeutic agent comprising a molecule having at least a first segment competent for importation of said molecule into mast cells in vivo, and a second segment for having an anti-allergic effect within said mast cells, said first segment being joined to said second segment through a linker, whereby the complex molecule is capable of exerting its anti-allergic effect in vivo ~~The method of claim 30, and~~ wherein said second segment is a peptide taken from the C terminal sequence of $G\alpha_t$.

Claim 45 (Currently Amended) The method of claim ~~30~~ 44, wherein said molecule is a peptide having an amino acid sequence AAVALLPAVLLALLAPKENLKDCGLF (SEQ ID NO:12).

Claim 46 (Currently Amended) The method of claim ~~30~~ 44, wherein said therapeutic agent further comprises a second molecule, said second molecule being a peptide having an amino acid sequence AAVALLPAVLLALLAPKNNLKECGLY (SEQ ID NO:7).

Claims 47-49 (Cancelled)

Claim 50 (Currently Amended) The method of claim ~~43~~ 44, wherein said molecule is a peptide having an amino acid sequence AAVALLPAVLLALLAPKNNLKECGLY (SEQ ID NO:7), and cyclic derivatives thereof, and wherein the molecule further comprises cyclization between lysine at position 17 and the C terminus of the peptide.

Claim 51 (Cancelled)